Navigation Links
Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
Date:1/26/2010

MONTREAL, Jan. 26 /PRNewswire/ - Aegera Therapeutics Inc. announced today the successful completion of a dose-ranging Phase 1 study and the initiation of a randomized Phase 2 study of AEG35156 in combination with sorafenib for the treatment of patients with advanced hepatocellular carcinoma (primary liver cancer).

This new study, entitled "A Phase 2, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination with Sorafenib in Patients With Advanced Hepatocellular Carcinoma", is being conducted in Hong Kong. The study is projected to recruit approximately 50 patients with two thirds receiving the combination of AEG35156 and sorafenib and one third receiving sorafenib alone.

"We are pleased with the conduct and results of the Phase 1 portion of this trial. AEG35156 appears to be well tolerated when given in combination with sorafenib. We are now focused on completing recruitment to the randomized Phase 2 portion of the clinical trial to determine if the AEG35156/sorafenib combination can bring an additional therapeutic benefit to this under-served oncology population," stated Dr. Jacques Jolivet, Senior Vice-President of Clinical Development of Aegera.

About AEG35156

AEG35156 is a 2nd generation antisense oligonucleotide which targets XIAP; it is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy, without harming healthy cells. Other currently enrolling studies include a randomized Phase 2 study for the treatment of acute myeloid leukemia and a Phase 1/2 monotherapy study in CLL/indolent B-cell lymphomas, which is fully funded by The Leukemia and Lymphoma Society of North America.

About Aegera Therapeutics Inc.


'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
8. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 2014  Origin Agritech Limited (NASDAQ GS: SEED) (" Origin ... crop seeds in China , today announced ... 2014 ended September 30, 2014, before the market opens on ... a teleconference on January 8, 2015, at 8:00 a.m. ET ... discuss the results. To participate in the call, please dial ...
(Date:12/13/2014)... The DNA Microarray market market was ... expected to grow at a CAGR of 15.2% ... TOC of the DNA Microarray for an in-depth ... help of various tables and figures. , ... consists of instrument, consumables, and services, where the ...
(Date:12/13/2014)... 2014  Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company ... Veronica G. H. Jordan , Ph.D., and ... Directors, bringing the total number of directors to eight, ... Jim LaFrance , Chairman, President, and Chief Executive Officer ... the appointments of Veronica and David to our board ...
(Date:12/12/2014)... Graphite Metallizing Corporation, the manufacturer of self-lubricating ... has appointed Kirk Staller as Sales Engineering Representative for ... a B.S. degree from Purdue University and has over ... of it with a manufacturer of centrifugal pumps. He ... , “We are pleased to have Kirk join ...
Breaking Biology Technology:Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 3Kirk Staller Joins Graphite Metallizing Corporation 2
... Switzerland, February 11 ,Acrongenomics, Inc. (OTCBB:AGNM), the Geneva ... and The Imperial Venture Fund a,time line for ... acquisition of 10.9% of the shares of Molecular ... agreed by all parties that the full,acquisition of ...
... Calif., Feb. 8 Anesiva,Inc. (Nasdaq: ANSV ) ... company,s board of directors. Mr. Janney previously served on ... transitioned off,the board following the merger of Anesiva and ... the Anesiva board of directors,and we are very pleased ...
... Medical today issued the,following response to a press release ... GmbH had achieved in the AIPPI in,AGA,s patent dispute ... sort was conducted before the AIPPI and that,organization agreed ... AGA has not been involved in any proceedings with ...
Cached Biology Technology:Acrongenomics on Track to Acquire Molecular Vision 2Acrongenomics on Track to Acquire Molecular Vision 3Acrongenomics on Track to Acquire Molecular Vision 4Anesiva Appoints Daniel Janney to Board of Directors 2Anesiva Appoints Daniel Janney to Board of Directors 3AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe 2
(Date:12/10/2014)... , December 9, 2014 ... ITN,s BCARD Platform   ... enterprise meeting scheduling solutions for business-to-business (B2B) events, ... world leader in mobile near-field communication (NFC), Bluetooth ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... Bees among agriculture,s hardest workers as key pollinators ... declined over the last half-century, with die-offs in recent ... a $1.5 million National Science Foundation (NSF) multi-institutional grant ... consolidate data from 10 natural history bee collections across ...
... An Australian scientist has discovered what could be the world,s ... unique Pacific elkhorn coral was found while conducting underwater surveys ... Dr Zoe Richards of the ARC Centre of Excellence for ... physical resemblance to the critically endangered and fast-vanishing elkhorn coral ...
... Energy,s (DOE) Argonne National Laboratory will lead projects that ... time at Argonne,s Leadership Computing Facility (ALCF). The ALCF ... capable of performing 557 trillion calculations per second, enabling ... or months rather than years. "By providing millions ...
Cached Biology News:New $1.5 million NSF grant to track bee declines and pollination 2Super-rare 'elkhorn' coral found in Pacific 2Super-rare 'elkhorn' coral found in Pacific 3Supercomputers take science by storm 2Supercomputers take science by storm 3
... degrades single-stranded DNA and RNA endonucleolytically ... acids (DNA:DNA, DNA:RNA or RNA:RNA) are ... high concentrations of enzyme (1). The ... termini from double-stranded DNA (2), for ...
... catalyzes the transfer of the ... 5-terminus of polynucleotides or to ... The enzyme, purified from recombinant ... to phosphorylate RNA, DNA and ...
... verticillus USBio Analyzed PRODUCT SPECIFICATIONS Form: White powder Assay: 1.5 ... units/ml): 4.5 to 6.0 Loss On Drying: less than or ... 0.1% Bleomycin Content: A 2 : 55 - 70% B ... : greater than or equal to 90% B 4 : ...
A powerful, easy-to-use solution, the SORVALL RC12BP Blood Processing System allows you to manufacture blood components quickly and cost-effectively while ensuring product quality, safety, and GMP co...
Biology Products: